Compressive Dressing and Pharyngocutaneous Fistula After Primary Total Laryngectomy (TIGHT)

November 15, 2026 updated by: Andrea Galli, IRCCS San Raffaele

Impact of Compressive Dressing on the Risk of Pharyngocutaneous Fistula After Primary Total Laryngectomy: A Multicenter Retrospective Observational Study

Pharyngocutaneous fistula (PCF) is one of the most feared complications after total laryngectomy. A compressive neck dressing is often applied after surgery to try to prevent it, but there is no consensus on whether it works or how long it should be kept, and practice varies widely between centers. This multicenter, retrospective, observational study compares the rate of PCF in adult patients with laryngeal squamous cell carcinoma who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa and who did or did not receive a postoperative compressive dressing. It also examines whether the duration of the dressing affects the risk of fistula and how fistulas were managed in the two groups. All data are collected from existing medical records; no additional treatment or examination is performed.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PCF occurs in about 14% of primary total laryngectomies and about 28% of salvage procedures. It is associated with prolonged hospital stay, higher costs, delayed adjuvant treatment, and further complications. No study has directly compared patients managed with and without a postoperative compressive dressing.

This is a non-profit, multicenter, national, retrospective observational study coordinated by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Consecutive patients who underwent primary total laryngectomy from January 1, 2014 to the study start date are included. All patients were treated according to routine clinical practice at each center. Patients are divided into two groups according to postoperative management: compressive dressing of the cervical region over the neopharyngeal suture (Group A) or no compressive dressing (Group B).

Data are extracted from medical records and entered in pseudonymized form in an electronic case report form (REDCap). Collected variables include demographics, smoking and alcohol use, comorbidities, preoperative laboratory values and inflammatory indices, tumor site and clinical stage, surgical details (neck dissection, thyroidectomy, pharyngeal closure technique, salivary stent, primary voice prosthesis), postoperative antibiotic protocol, time to oral feeding, and fistula characteristics and management.

The planned sample size is 950 patients (475 per group), which provides 80% power to detect a 6.0% difference in fistula rate between groups, assuming a baseline rate of 14.3% in the group without compressive dressing, using a two-sided Fisher's exact test with alpha 0.05. The primary outcome will be analyzed with Fisher's exact test. Secondary outcomes will be analyzed with logistic and linear regression. Confounding will be addressed with propensity score matching, inverse probability weighting, or covariate adjustment, as appropriate.

Study Type

Observational

Enrollment (Estimated)

950

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bergamo, Italy
        • Recruiting
        • ASST Papa Giovanni XXIII
        • Contact:
      • Bologna, Italy
        • Recruiting
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
        • Contact:
          • Edoardo Serafini, Medical Degree
          • Phone Number: +39 051 2145263
      • Bologna, Italy
        • Recruiting
        • Ospedale Maggiore Carlo Alberto Pizzardi
        • Contact:
      • Bolzano, Italy
        • Recruiting
        • Ospedale Centrale di Bolzano
        • Contact:
          • Luca Calabrese, medical degree
          • Phone Number: +39 0471 438641
          • Email: orlbz@sabes.it
      • Brescia, Italy
        • Recruiting
        • ASST degli Spedali Civili di Brescia
        • Contact:
      • Candiolo, Italy
        • Recruiting
        • IRCCS Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
        • Contact:
      • Cesena, Italy
      • Florence, Italy
        • Recruiting
        • Azienda Ospedaliero-Universitaria Careggi
        • Contact:
          • Giandomenico Maggiore, Medical Degree
          • Phone Number: +39 055 7942000
      • Forlì, Italy
        • Recruiting
        • Ospedale G.B. Morgagni - L. Pierantoni
        • Contact:
      • Milan, Italy
      • Milan, Italy
      • Modena, Italy
        • Recruiting
        • Azienda Ospedaliero-Universitaria Policlinico di Modena
        • Contact:
      • Naples, Italy
      • Padova, Italy
        • Recruiting
        • Azienda Ospedale-Università di Padova
        • Contact:
      • Pavia, Italy
        • Recruiting
        • Fondazione IRCCS Policlinico San Matteo
        • Contact:
      • Pescara, Italy
      • Ravenna, Italy
      • Reggio Emilia, Italy
        • Recruiting
        • Arcispedale Santa Maria Nuova
        • Contact:
      • Rimini, Italy
      • Roma, Italy
      • Roma, Italy
      • Roma, Italy
      • Torino, Italy
        • Recruiting
        • AOU Città della Salute e della Scienza (Molinette)
        • Contact:
      • Trieste, Italy
        • Recruiting
        • Ospedale di Cattinara
        • Contact:
          • Giancarlo Tirelli, Medical Degree
          • Phone Number: +39 040 3994933
          • Email: tirellig@units.it
      • Verona, Italy
        • Recruiting
        • Azienda Ospedaliera Universitaria Integrata di Verona
        • Contact:
      • Vittorio Veneto, Italy
        • Recruiting
        • Ospedale di Vittorio Veneto - ULSS 2 Marca Trevigiana
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive adult patients with squamous cell carcinoma of the larynx who underwent primary total laryngectomy with direct closure of the hypopharyngeal mucosa at the participating Italian otolaryngology centers from January 1, 2014 to the study start date.

Description

Inclusion Criteria:

  • Squamous cell carcinoma of the larynx treated with primary total laryngectomy
  • Primary closure of the hypopharyngeal mucosa
  • Age 18 years or older
  • Informed consent to study participation and to personal data processing
  • Availability of data on comorbidities, laboratory parameters, and postoperative management

Exclusion Criteria:

  • Salvage total laryngectomy
  • Previous radiotherapy or chemoradiotherapy to the head and neck
  • Previous open surgery of the pharyngolaryngeal region
  • Reconstruction with a free or pedicled flap (inlay or onlay)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Compressive dressing (Group A)

Patients who received a postoperative compressive dressing of the cervical region over the neopharyngeal suture after primary total laryngectomy, according to routine clinical practice at the treating center.

Postoperative compressive dressing applied to the cervical region over the neopharyngeal suture. This is an exposure observed in routine clinical practice; it is not assigned by the study.

No compressive dressing (Group B)

Patients who did not receive a postoperative compressive dressing after primary total laryngectomy, according to routine clinical practice at the treating center.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of pharyngocutaneous fistula
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients who develop a pharyngocutaneous fistula in each group (compressive dressing vs no compressive dressing).

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of pharyngocutaneous fistula by duration of compressive dressing
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients in Group A who develop a pharyngocutaneous fistula, stratified by duration of the compressive dressing (days).

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to onset of pharyngocutaneous fistula
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from surgery to diagnosis of pharyngocutaneous fistula in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Type of management of pharyngocutaneous fistula
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients with fistula managed conservatively (compressive dressing) or surgically in each group.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Resolution of pharyngocutaneous fistula
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number and percentage of patients whose fistula resolved, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days
Time to resolution of pharyngocutaneous fistula
Time Frame: During the postoperative hospital stay (from surgery to discharge), up to 60 days

Number of days from diagnosis to resolution of the fistula, by initial group and type of management.

During the postoperative hospital stay (from surgery to discharge), up to 60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Edoardo Serafini, Medical Degree, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2025

Primary Completion (Estimated)

January 5, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

November 15, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 162/2025/Oss/AOUBo

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data underlying the published results will be made available upon reasonable request to the Principal Investigator.

IPD Sharing Time Frame

After publication of the study results in a peer-reviewed journal.

IPD Sharing Access Criteria

Data will be shared with researchers who submit a motivated request to the Principal Investigator of the coordinating center (IRCCS Azienda Ospedaliero-Universitaria di Bologna).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.